# Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)

> **NCT00472927** · PHASE1 · COMPLETED · sponsor: **Wyeth is now a wholly owned subsidiary of Pfizer**

## Conditions studied

- Postmenopause

## Interventions

- **DRUG:** Premarin/MPA 0.45 mg/1.5 mg

## Key facts

- **NCT ID:** NCT00472927
- **Lead sponsor:** Wyeth is now a wholly owned subsidiary of Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** —
- **Final completion:** 2007-08
- **Target enrollment:** — (—)
- **Last updated:** 2007-12-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00472927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00472927, "Bioequivalence Study of 3 New Formulations of Premarin/MPA Compared With Premarin/MPA (Prempro)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT00472927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*